EE517 Cost-Effectiveness Analysis of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Greece
Karaiskou, M., Avgitidou, A., Vostitsanou, Z., Batsi, M., Bungey, G., Prawitz, T., Peter, B., Stafylas, P.
Published in Value in health (01.12.2023)
Published in Value in health (01.12.2023)
Get full text
Journal Article
POSB23 Tafasitamab Plus Lenalidomide (T-L) Versus Standard of Care (SoC) Including 3 Rituximab-Based Treatments or Lenalidomide Monotherapy in Patients with Non-Transplant Eligible Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NTE R/R DLBCL): A Matching Adjusted Indirect Treatment Comparison (MAIC)
Córdoba, R, Prawitz, T, Westley, T, Sharma, A, Kapetanakis, V, Sabatelli, L
Published in Value in health (01.01.2022)
Published in Value in health (01.01.2022)
Get full text
Journal Article
POSB74 Belantamab Mafodotin as the First-in-Class Anti-BCMA Treatment for Relapsed/Refractory Multiple Myeloma: A Budget Impact and Cost-Effectiveness Analysis
Speranza, G, Diliberto, MJ, Fattore, C, Fiorentino, F, Prawitz, T, Nikolaou, A, Samele, R
Published in Value in health (01.01.2022)
Published in Value in health (01.01.2022)
Get full text
Journal Article
CO8 Ponatinib vs Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia: A Matching Adjusted Indirect Comparison
Ribera Santasusana, J.M., Prawitz, T., Freitag, A., Sharma, A., Dobi, B., Rizzo, F., Sabatelli, L., Patos, P.
Published in Value in health (01.12.2022)
Published in Value in health (01.12.2022)
Get full text
Journal Article
MSR149 Cost-Effectiveness Model Conceptualisation in Chronic Graft Versus Host Disease
Elisheva, L., Abdul Jabbar, O.A., Kongnakorn, T., Houisse, I., Hudson, R., Skinner, L., Szabó, G., Prawitz, T., Dobi, B., Nicholls, C.
Published in Value in health (01.12.2023)
Published in Value in health (01.12.2023)
Get full text
Journal Article
36P Indirect comparison of mobocertinib trial data vs real-world data in patients with EGFR exon 20 insertion (ex20ins)+ non-small cell lung cancer (NSCLC)
Christopoulos, P., Prawitz, T., Hong, J-L., Lin, H.M., Hernandez, L., Jin, S., Tan, M., Proskorovsky, I., Lin, J., Zhang, P., Patel, J., Ou, S-H.I., Thomas, M., Stenzinger, A.
Published in Annals of oncology (01.04.2022)
Published in Annals of oncology (01.04.2022)
Get full text
Journal Article
901P Matching-adjusted indirect comparisons (MAIC) of safety between single-agent belantamab mafodotin versus selinexor plus dexamethasone in relapsed/refractory multiple myeloma (RRMM)
Suvannasankha, A., Prawitz, T., Kapetanakis, V., Sarri, G., Hughes, R., Wang, F., Hogea, C., Allen Ferrante, S., Gutierrez, B., Gorsh, B., Willson, J., Popat, R.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
PCN280 - IMPACT OF SUBOPTIMAL CLINICAL EVIDENCE ON HEALTH TECHNOLOGY ASSESSMENT RECOMMENDATIONS
Zou, D., Desrosiers, N., Wu, S., Prawitz, T., Tervonen, T., Marsh, K., Caro, J.J.
Published in Value in health (01.10.2018)
Published in Value in health (01.10.2018)
Get full text
Journal Article
PIN86 CLINICAL AND ECONOMIC OUTCOMES ASSOCIATED WITH VARYING COVERAGE OF VARICELLA VACCINATION STRATEGIES IN SWITZERLAND
Heininger, U., Wolfson, L., Lienert, F., Kyle, J., Sutton, K., Guggisberg, P., Prawitz, T., O'Brien, E., Gani, R., Pawaskar, M.
Published in Value in health (01.11.2019)
Published in Value in health (01.11.2019)
Get full text
Journal Article
Assessment-Time Bias: Statistical Approaches to Adjusting for Between-Trial Differences in the Schedule of Assessment for Disease Progression In Immuno-Oncology Trials
Kapetanakis, V, Schlichting, M, Stevens, JW, Prawitz, T, Kearney, M, Phatak, H, Benedict, A, Bharmal, M
Published in Value in health (01.05.2018)
Published in Value in health (01.05.2018)
Get full text
Journal Article
CP3 - Assessment-Time Bias: Statistical Approaches to Adjusting for Between-Trial Differences in the Schedule of Assessment for Disease Progression In Immuno-Oncology Trials
Kapetanakis, V, Schlichting, M, Stevens, JW, Prawitz, T, Kearney, M, Phatak, H, Benedict, A, Bharmal, M
Published in Value in health (01.05.2018)
Published in Value in health (01.05.2018)
Get full text
Journal Article
PCV75 - AN UPDATED COST-EFFECTIVENESS PAIRWISE ANALYSIS OF APIXABAN AND WARFARIN FOR STROKE PREVENTION IN PATIENTS WITH NON- VALVULAR ATRIAL FIBRILLATION IN FRANCE
Lanitis, T., Bregman, B., Maunoury, F., Prawitz, T., Gaudin, A., Cotté, F.
Published in Value in health (01.10.2018)
Published in Value in health (01.10.2018)
Get full text
Journal Article